Peginterferon with NA to prevent liver cancer in hepatitis B
Part of Infections clinical trials.
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have had a positive HBsAg test (hepatitis B surface antigen) for at least 6 months.
- You have a family history of liver cancer (in parents, children, siblings, grandparents, aunts, or uncles).
- You are planning to take or already taking peginterferon alpha-2b with a nucleoside analog, or a nucleoside analog alone.
- You are not allergic to interferon, do not have advanced liver cirrhosis, certain blood cell counts are adequate, and you are not pregnant or planning pregnancy within 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called peginterferon alfa-2b to see if it can help children with chronic hepatitis B achieve a functional cure, meaning the virus stays under control. If your child has hepatitis B, this treatment might improve their chances of clearing the infection.
This study is looking at how well antiviral treatments work to prevent liver cancer in people with chronic hepatitis B who have a family history of the disease. If you are over 30 and taking antiviral medication, you may be able to join.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This trial tests a medication (pegylated interferon alfa-2b) for people with hepatitis B-related liver cancer that has been completely removed by surgery or ablation. The goal is to see if this treatment can help prevent the cancer from coming back.
This study tests a drug called peginterferon alfa-2b for people with advanced liver cancer that cannot be removed by surgery and who also have hepatitis B. The drug aims to boost the immune system to fight the cancer and may help control the disease.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.